drugset / Trial / NCT05954286
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Phase 2
Completed
92 enrolled
Henry M. Jackson Foundation for the Advancement of Military Medicine
FHI Clinical, Inc. · collabJoint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies · collabRedHill Biopharma Limited · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Timeline
- Start
- 2024-01-29
- Primary completion
- 2025-04-24
- Completion
- 2025-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Upamostat | Small molecule | 400 mg | Oral |